Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCISE
2023-506967-33-00Phase 2Completed
- Sponsor
- University College Dublin
- Start
- Feb 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of colchicine in ischemic stroke, transient ischaemic attack (TIA), atherosclerosis and 2 more, sponsored by University College Dublin. Primary endpoint: Change in inflammatory biomarker panel. Started Feb 2024; status: completed.
02
Drugs
colchicine
03
Conditions
ischemic stroketransient ischaemic attack (TIA)atherosclerosiscoronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on 2023-506967-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506967-33-00.